Determination of a New Biomarker at the Level of Gene Alteration in Cisplatin Ototoxicity
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26188880 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Deniz Kızmazoğlu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Institute of Oncology, Dokuz Eylül University, Izmir 35340, Turkey. Hauptthemen laut MEDLINE: Cisplatin, Ototoxicity, Antineoplastic Agents, Hearing Loss. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Turkish Pediatric Oncology Group (TPOG) under the 2022 Research Projects Support Program, Dokuz Eylül University.
Abstract (Originalsprache)
Cisplatin is an alkylating chemotherapeutic drug used in the treatment of many pediatric solid tumors, and cisplatin ototoxicity is characterized by sensorineural, bilateral, irreversible, and progressive hearing loss. The aim of this study is to identify biomarkers that may serve as predictors of cisplatin-induced ototoxicity in pediatric cancers. In our preliminary study, patients with severe hearing loss were analyzed using the comparative genomic hybridization (CGH) method. Mutations were identified in the following genes: ADAM6, SIX3, GNAS, NDUFV1, H19, DEFA4, and ZIM2. Based on these data, we aimed to investigate the mutation status of these candidate genes in a larger population of pediatric cancer patients treated with cisplatin. DNA samples were extracted from the mononuclear cells of peripheral blood samples obtained from 82 patients. These genes were analyzed using the RT-PCR technique, and ototoxicity was assessed using the Brock and Muenster classifications. Hearing loss was detected in 28% of patients; 76.8% and 23.2% had mild and severe hearing loss, respectively. A significant correlation was found between ZIM2 gene amplification and the presence of ototoxicity (rho = 0.461, p = 0.003), especially in advanced-stage cancer patients with severe hearing loss (rho = 0.38, p = 0.017). Our findings suggest that ZIM2 is a promising biomarker for predicting cisplatin ototoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Oncology, Institute of Oncology, Dokuz Eylül University, Izmir 35340, Turkey.
- Department of Basic Oncology, Institute of Oncology, Dokuz Eylül University, Izmir 35340, Turkey.
- Department of Otorhinolaryngology, Faculty of Medicine, Dokuz Eylül University, Izmir 35340, Turkey.
- Department of Medical Biology, Faculty of Medicine, Izmir University of Economics, Izmir 35330, Turkey.
- Acıbadem Kent Hospital, Karsıyaka, Izmir 35630, Turkey.
ORCID-Profile: Deniz Kızmazoğlu, Ayşe Banu Demir, Safiye Aktaş
Förderung
- Turkish Pediatric Oncology Group (TPOG) under the 2022 Research Projects Support Program
- Dokuz Eylül University
Zitieren
APA
Kızmazoğlu, D., Erol, A., Aktaş, T. Ç., Olgun, Y., Demir, A. B., Altun, Z., Aktaş, S., & Olgun, N. (2025). Determination of a New Biomarker at the Level of Gene Alteration in Cisplatin Ototoxicity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26188880
Vancouver
Kızmazoğlu D, Erol A, Aktaş TÇ, Olgun Y, Demir AB, Altun Z, et al. Determination of a New Biomarker at the Level of Gene Alteration in Cisplatin Ototoxicity. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26188880
BibTeX
@article{Kzmazolu2025,
author = {Kızmazoğlu, Deniz and Erol, Aylin and Aktaş, Tekincan Çağrı and Olgun, Yüksel and Demir, Ayşe Banu and Altun, Zekiye and Aktaş, Safiye and Olgun, Nur},
title = {Determination of a New Biomarker at the Level of Gene Alteration in Cisplatin Ototoxicity},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26188880}
}
EUVIMED